Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

Key Points

• Mutual of America Capital Management LLC increased its stake in Vericel Corporation by 5.9%, owning approximately 158,930 shares now valued at $7,091,000 as of its latest SEC filing.
• Vericel recently reported a net margin of 2.85% and a year-over-year revenue increase of 20.1%, with earnings per share surpassing analysts' expectations.
• Analysts maintain a generally positive outlook on Vericel, with an average rating of "Moderate Buy" and a consensus price target of $59.86.

Mutual of America Capital Management LLC boosted its position in Vericel Corporation (NASDAQ:VCEL - Free Report) by 5.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,930 shares of the biotechnology company's stock after buying an additional 8,789 shares during the period. Mutual of America Capital Management LLC owned approximately 0.32% of Vericel worth $7,091,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. LPL Financial LLC boosted its holdings in shares of Vericel by 27.6% in the fourth quarter. LPL Financial LLC now owns 56,674 shares of the biotechnology company's stock valued at $3,271,000 after acquiring an additional 12,268 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Vericel by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 1,166,115 shares of the biotechnology company's stock valued at $64,046,000 after purchasing an additional 12,062 shares in the last quarter. Wells Fargo & Company MN increased its position in Vericel by 11.8% during the 4th quarter. Wells Fargo & Company MN now owns 69,975 shares of the biotechnology company's stock worth $3,842,000 after purchasing an additional 7,363 shares during the period. Bank of Montreal Can increased its position in Vericel by 17.3% during the 4th quarter. Bank of Montreal Can now owns 6,217 shares of the biotechnology company's stock worth $341,000 after purchasing an additional 919 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Vericel by 11.5% during the 4th quarter. Renaissance Technologies LLC now owns 89,500 shares of the biotechnology company's stock worth $4,914,000 after buying an additional 9,200 shares in the last quarter.

Vericel Stock Down 0.4%

Shares of VCEL stock opened at $36.15 on Friday. The stock has a market cap of $1.82 billion, a P/E ratio of 301.28 and a beta of 1.27. Vericel Corporation has a fifty-two week low of $33.09 and a fifty-two week high of $63.00. The business has a fifty day simple moving average of $40.43 and a 200-day simple moving average of $44.97.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.03. The firm had revenue of $63.24 million for the quarter, compared to analysts' expectations of $64.61 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The firm's revenue was up 20.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.10) EPS. On average, sell-side analysts anticipate that Vericel Corporation will post 0.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on VCEL shares. Stephens restated an "overweight" rating and issued a $67.00 price target on shares of Vericel in a research note on Monday, June 16th. Truist Financial decreased their target price on shares of Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Wall Street Zen downgraded shares of Vericel from a "hold" rating to a "sell" rating in a report on Monday, May 12th. Finally, Canaccord Genuity Group reduced their price objective on shares of Vericel from $61.00 to $58.00 and set a "buy" rating for the company in a research note on Friday, August 1st. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $59.86.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.